Drug intelligence / Profile preview

mi-APO

Development stage: Preclinical
Lead developer: Multimmune
Modality: Recombinant Proteins and Enzymes

Overview

mi-APO is a preclinical recombinant protein therapeutic being developed by Multimmune for the treatment of tumors that express membrane-bound heat shock protein 70 (Hsp70). The drug is a recombinant human granzyme B-based agent designed to exploit membrane Hsp70 as a tumor-specific portal. Upon binding to membrane Hsp70, mi-APO is internalized into the tumor cells in a perforin-independent manner, where it subsequently triggers the caspase cascade and induces apoptosis, selectively destroying Hsp70-positive cancer cells while sparing normal tissues.

Targets

HSP70 (Heat shock protein 70)

Beyond the preview

Go deeper on mi-APO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mi-APO.